Bone marrow mononuclear cell transplantation improved cardiac function of rat doxorubicin-induced cardiomyopathy model

Bone Marrow Cell Transplantation into the Heart is Not a Crucial Factor of Ventricular Fibrillation in a Rat Doxorubicin-Induced Cardiomyopathy Model

“…Doxorubicin-induced cardiomyopathy was generated as described by our previous study. 4) In brief, doxorubicin hydrochloride (Sigma Chemical Co., St. Louis, USA) (2.5 mg/kg  6 within 2 weeks) was intraperitoneally administrated to the rats. They were randomly divided into two groups: Cell transplantation group (D-TX) and non-cell transplantation group (D-N).…”

“…At 4 weeks after the final administration of doxorubicin hydrochloride, bone marrow cell transplantation into the heart was performed for rats in D-TX. 4) We prepared BMMNC from other syngenic normal rats just prior to the cell transplantation. The rats were anesthetized with an intramuscular administration of ketamine hydrochloride (3 mg), and an intraperitoneal injection of sodium pentobarbital (10 mg) and heparin (100 units).…”

“…Numerous animal studies have shown evidence that cell transplantation improves cardiac function. [1][2][3][4] These studies reported that arrhythmia was not detected after cell transplantation by conven-tional methods such as electrocardiographic monitorings. 5) Based on these previous studies, clinical trials for ischemic heart disease were started.…”

“…In our previous study, we have reported that bone marrow mononuclear cell transplantation had favorable effects in a rat doxorubicin-induced cardiomyopathy model in terms of systolic cardiac function, the concentration of atrial natriuretic peptide, and myocardial ultrastructures evaluated by electron and light microscopic study. 4) On the basis of this experiment, we next focused on one of the very important issues of arrhythmia related to cell transplantation using the same animal model. To clarify this issue, we evaluated ventricular fibrillation thresholds (VFT) using the train-stimuli technique 11,12) and action potential duration (APD) using monophasic action potential (MAP) recording, 13) both of which are conventional methods in electrophysiology, after bone marrow cell transplantation for a rat doxor-ubicin-induced cardiomyopathy model, 4) and verified whether bone marrow transplantation would suppress arrhythmogenicity of the diseased heart.…”

Cell‐based Therapy to Regenerate Myocardium: from Bench to Bedside

“…Few reports regarding cell transplantation in an IDCM model have been published, with those published having used fetal cardiomyocytes (23), heart cells (24) and skeletal myoblasts (25). We reported the feasibility of BMMNC transplantation for nonischemic cardiomyopathy using a rat doxorubicin‐induced cardiomyopathy model (26). Some patients are able to be weaned from their left ventricular assist device (LVAD) due to an as‐yet‐unknown mechanism (27).…”